- MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights
- MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
- MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
- MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
- MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
More ▼
Key statistics
On Thursday, MEI Pharma Inc (MEIP:NAQ) closed at 2.82, 3.32% above its 52-week low of 2.73, set on Jun 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.90 |
---|---|
High | 2.91 |
Low | 2.78 |
Bid | 2.50 |
Offer | 2.99 |
Previous close | 2.88 |
Average volume | 31.71k |
---|---|
Shares outstanding | 6.66m |
Free float | 6.62m |
P/E (TTM) | 0.7286 |
Market cap | 19.06m USD |
EPS (TTM) | 3.93 USD |
Data delayed at least 15 minutes, as of Jun 06 2024 20:59 BST.
More ▼